Acceleron Pharma Appoints Matthew L. Sherman, M.D. as Chief Medical Officer
Dr. Sherman's Expertise in Building a Clinical Development Organization and Advancing Programs Through Regulatory Approval a Key Addition to the Management Team
5/16/2006 - Acceleron Pharma, Inc., a biopharmaceutical company focused on developing and commercializing therapeutics based on its novel tissue growth factor platform, today announced the appointment of Matthew L. Sherman, M.D. as Senior Vice President and Chief Medical Officer.
Ensemble Discovery Appoints Nick Terrett, PhD as Chief Scientific Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 22, 2006--Ensemble Discovery Corporation today announced the appointment of Nick Terrett, PhD to the newly created role of Chief Scientific Officer. In this capacity, Dr. Terrett will oversee all of Ensemble Discovery's pharmaceutical research and development activities.
CombinatoRx Reports Second Positive Phase 2 Study with CRx-102
Achieved Primary Endpoint with Statistically Significant Reduction in C-Reactive Protein in Human Inflammatory Model
Helicos BioSciences Announces First "Early Access" Partnership with Institute for Systems Biology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 7, 2006--Helicos BioSciences, a pioneer in high-speed, high-sensitivity sequencing, today announced a new partnership with the Institute for Systems Biology (ISB) as the company's first "Early Access" program research collaborator. The ISB is an internationally renowned non-profit research institute dedicated to the study and application of systems biology. The partnership will allow the ISB access to Helicos' True Single Molecule Sequencing (tSMS(TM)) technology and protocols for use in its scientifically groundbreaking research projects.
Morphotek Announces Initiation of Phase II Clinical Studies For MORAb-003 in Ovarian Cancer
EXTON, Pa., June 8 /PRNewswire/ -- Morphotek, Inc. today announced initiation of Phase II efficacy studies in major cancer centers worldwide for its anti-cancer antibody MORAb-003. MORAb-003 is a monoclonal antibody that targets the folate receptor alpha (FRA), a target over-expressed in over 90% of ovarian cancers and a number of other solid tumors. The antibody works via suppression of FRA-mediated signal transduction and induces tumor-specific cytotoxicity by both antibody dependent cellular and complement mediated immune-effector mechanisms.
Helicos BioSciences Names Steve Lombardi Senior Vice President of Marketing
6/14/2006 8:00:00 AM EST -- Helicos BioSciences, a pioneer in high-speed, high-sensitivity sequencing, today announced that it has named longtime biotechnology executive Steve Lombardi as Senior Vice President of Marketing.
Compound Therapeutics Becomes AdNexus Therapeutics
Company Continues to Advance the AdNectin Therapeutic Class
Waltham, MA, June 21, 2006– Compound Therapeutics, Inc., a private biotechnology company focused on development of medicines based on AdNectins™, today announced it has changed its name to Adnexus Therapeutics, Inc.. The company’s new website will be www.adnexustx.com
First AdNectin Therapeutic, CT-322, Clears FDA IND Review to Start Clinical Trials
Anti-Cancer Therapeutic is a First in a Broadly Applicable, Innovative Class of Targeted Therapeutics
Acceleron Initiates Phase 1 Clinical Trial of ACE-011, a Novel Treatment for Bone Loss
Acceleron Becomes a Clinical-Stage Company
Adnexus Therapeutics Closes $27M Series B Funding
Series B Financing Led by Venrock will Advance Breakthrough New Product Class, AdNectins